ArticleFrontiers in pharmacology2026
Structure-guided hydrophobic modulation at the 3-position of
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypertension is a major global health challenge driven by sustained alterations in vascular tone and dysregulation of the renin-angiotensin system (RAS). Although natural products provide valuable scaffolds for vascular drug discovery, systematic structure-function studies linking defined hydrophobic modifications to vascular mechanisms remain limited. This study aimed to evaluate how hydrophobic substitution at the three-position of chalcones derived from Methods: A focused series of chalcones bearing either an allyl or a prenyl substituent at the three-position was synthesized and evaluated. Vasorelaxant effects were assessed in isolated aortic rings from spontaneously hypertensive rats under receptor-mediated (phenylephrine), depolarization-induced (KCl), and angiotensin I-induced contractile conditions. Molecular docking studies were performed to explore interactions with the angiotensin-converting enzyme (ACE) catalytic site, and Results: All chalcones induced concentration-dependent relaxation in precontracted aortic rings; however, their pharmacological profiles depended on the nature of the 3-substituent. The prenylated derivative CHAL 13 showed the most consistent activity across complementary vascular models, retaining inhibitory effects under depolarizing conditions and significantly attenuating angiotensin I-induced contraction. In contrast, the allylated derivative CHAL A showed a more limited mechanistic profile: although retaining activity in phenylephrine-precontracted rings, it exhibited weaker inhibition under depolarizing conditions and markedly lower ACE inhibitory potency Conclusion: Hydrophobic substitution at the three-position is a relevant determinant of the vascular behavior of S. nutans-derived chalcones. Prenylation favors a broader vasoactive profile associated with interference in Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.